This work uncovered DDR vulnerability in PTCL and indicates that targeting this pathway, particularly through ATR inhibition, is a viable and novel therapeutic strategy for PTCL. This evidence concerns the gene ATR and mature T-cell and NK-cell non-Hodgkin lymphoma.